Premium
Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer
Author(s) -
Sawada Yugo,
Omoto Kazuya,
Kohei Naoki,
Sakaguchi Kengo,
Miura Masahiko,
Tanabe Kazunari
Publication year - 2015
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.12753
Subject(s) - du145 , medicine , prostate cancer , angiogenesis , prostate , radiosensitizer , immunohistochemistry , cancer , pathology , staining , h&e stain , radiation therapy , cancer research , lncap
Objectives To examine the effects of combined treatment with sulfoquinovosylacylpropanediol and X‐ray irradiation on the remodeling of the prostate cancer microenvironment, including angiogenic and hypoxic characteristics. Methods Human prostate cancer cells (DU145 and PC3) were implanted subcutaneously into the right hind legs of athymic nude mice. After the tumor volume reached 100–300mm 3 , 2mg/kg/day sulfoquinovosylacylpropanediol was given intravenously from day0 to day4, and cells were exposed to 4Gy X‐ray irradiation on days0 and 3 (for a total of 8Gy). Tumors were fixed and stained for pathological analyses and immunohistochemical evaluations. To analyze vascular normalization, 60mg/kg pimonidazole dissolved in saline was injected intraperitoneally. Results Combined treatment with sulfoquinovosylacylpropanediol plus X‐ray irradiation enhanced growth inhibition in DU145 xenografts. The tumor vessel density in DU145 cells significantly decreased after the combined treatment. Staining for αsmooth muscle actin in vessels was significantly increased. Pimonidazole staining, showing hypoxic lesions, was negative from 72h, but positive at 6 and 24h after the first combined treatment. In contrast, no enhancement of the microenvironment in PC3 xenografts was observed with sulfoquinovosylacylpropanediol plus X‐ray irradiation. Conclusion Sulfoquinovosylacylpropanediol could be a novel potent radiosensitizing agent targeting angiogenesis in prostate cancer.